Blaine Rathmann is a clinical scientist at HiberCell. He is fascinated by the complex interactions of the tumor microenvironment and immune cells.
Prior to HiberCell, Blaine was working at the University of Minnesota performing research in adoptive cell therapies, focusing on CAR-T, TCR-engineered and TIL therapies. Blaine started his career with Biothera Pharmaceuticals, where he played a key role in performing and developing clinical assays to support the advancement of a novel cancer immunotherapy drug compound.
Blaine earned a B.S. in cell and molecular biology from Winona State University.